Some of the projects that we have completed in the past:

Diabetes-associated biomarkers - 5,808 assays

Nested case-control study of IGFs and prostate cancer risk in EPIC | "The epidemiology and aetiology of high risk prostate cancer" - 4,260 assays

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial – 10,000 assays

The CALERIE and parallel mouse study sample

The Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study – 10,000 assays

The Prostate Cancer Prevention Trial (PCPT) – 20,000 assays

Department of Defense (DOD) Prostate Cancer Research Program Development award: Distinguishing Lethal from Indolent Prostate Cancer with Free Insulin-Like Growth Factor Levels

The Transdisciplinary Research on Energetics and Cancer (TREC) Study – 5,000 assays

The Nurses’ Heath Study (NHS) – 73,000 assays

The Health Professionals Follow-Up Study (HPFS) – 10,000 assays

The Physicians’ Health Study (PHS I and II) – 31,000 assays

Endogenous hormones and postmenopausal breast cancer: Etiologic insights and improving risk prediction

The Cardiovascular Health Study (CHS) – 10,000 assays

National Cancer Institute of Canada Clinical Trial Group - A Randomized Trial of Antiestrogen Therapy versus Combined Antiestrogen and Octreotide Therapy in the Adjuvant Treatment of Breast Cancer in Post-Menopausal Women (NCIC CTG MA14 study) – 1000 assays

American Cancer Society Cancer Prevention Study (CPS) – 7,000 assays

Laval University Breast Density Study – 5,500 assays

EPIC pancreatic cancer

Clues to Heart Diseases and Cancer (CLUE) – 546 assays

Hawai’i Multi-Ethnic Cohort Study

  • PPG1 - 10,000 assays
  • PPG2 – 7,200 assays

Prostate Cancer Case Control Study – 1,500 assays

NIH Kidney Cancer Study – 5,324 assays

Back to top